TOMI Expands SteraMist Footprint in Europe with Ireland BPR Approval
Event summary
- TOMI's Binary Ionization Technology (BIT) received approval in Ireland under the EU's Biocidal Products Regulation (BPR) on August 17, 2026.
- Approval extends SteraMist's reach to 11 European markets, including key life sciences hubs.
- Ireland is home to over 90 pharmaceutical companies, including nine of the world's top 10.
- BIT is approved for professional indoor use across medical, industrial, and commercial sectors.
The big picture
TOMI's Ireland approval strengthens its position in Europe's most demanding contamination-control markets. The move comes as life sciences firms increasingly prioritize validated decontamination protocols across multi-country operations. Ireland's status as a global pharmaceutical hub amplifies the strategic significance of this regulatory win.
What we're watching
- Market Penetration
- How TOMI will leverage Ireland's concentrated life sciences sector to gain market share against established competitors.
- Regulatory Dynamics
- Whether TOMI can sustain approval momentum across remaining EU markets with similarly stringent standards.
- Customer Adoption
- The pace at which U.S.-based pharmaceutical customers expand contamination-control programs into Europe.
Related topics